Hemasphere

Papers
(The H4-Index of Hemasphere is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal150
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia69
Hypoferremia is Associated With Increased Hospitalization and Oxygen Demand in COVID‐19 Patients58
Azacytidine Treatment for VEXAS Syndrome56
Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments56
EHA2021 Virtual Congress Abstract Book50
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study50
Hemophilia Gene Therapy: Approaching the First Licensed Product48
Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results46
EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer44
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party42
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma35
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future33
Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up31
SARS-CoV-2 Vaccines in Patients With Multiple Myeloma31
EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-1930
Treatment for Relapsed/Refractory Acute Myeloid Leukemia30
Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies30
Functional Consequences of Mutations in Myeloproliferative Neoplasms27
Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms27
Endothelial and Complement Activation As Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation26
UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia26
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report25
P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL25
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA24
Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations24
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories24
Metabolic Regulation of Hematopoietic Stem Cells24
0.2667989730835